Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
115 Results for "
PLC
" in MedChemExpress (MCE) Product Catalog:
Products (115)
115 Results for "PLC" in MCE Product Catalog:
Cat. No.: HY-172567
Research Areas:
PLC thio-PIP2 trisodium is an analog of naturally occurring PIP2. PLC thio-PIP2 trisodium can simulate the process of PIP2 being hydrolyzed by PLC in in vitro experiments, and then quantitatively analyze the activity of PLC by detecting the free thiol produced by hydrolysis .
Cat. No.: HY-N15873
CAS No.: 2770684-26-7
Target:
Research Areas:
XY-69 triethylamine is a fluorescent analog of PIP2. XY-69 liposomal assay can be utilized in monitoring PLC enzymatic activity .
Cat. No.: HY-110119
CAS No.: 1780260-20-9
Target:
Research Areas:
Galloflavin potassium is a novel lactate dehydrogenase inhibitor that can be used for the research of cancer. Galloflavin inhibits aerobic glycolysis in PLC/PRF/5 cells and triggers cell death via apoptosis .
Cat. No.: HY-155513
CAS No.: 2568963-01-7
Syk-IN-8 (compound 19q) is a Syk inhibitor, with antiproliferative activity against multiple hematological tumour cells. Syk-IN-8 inhibits PLCγ2 phosphorylation, can be used for research in blood cancers .
Cat. No.: HY-12598AR
CAS No.: 146255-66-5
Synonyms: (RS)-3,5-DHPG (Standard)
Target:
Research Areas:
DHPG (Standard) is the analytical standard of DHPG. This product is intended for research and analytical applications. DHPG is the agonist for mGluR 1/5 (EC50 for mGluR 1 is 60 nM) that activates the phospholipase C (PLC) pathway, and leads ultimately to the activation of protein kinase C (PKC) .
Cat. No.: HY-146672
CAS No.: 2404604-06-2
ITK inhibitor 6 (compound 43) is a potent and selective ITK inhibitor with IC50s of 4 nM, 133 nM, 320 nM, 2360 nM, 155 nM for ITK, BTK, JAK3, EGFR, LCK, respectively. ITK inhibitor 6 inhibits phosphorylation of PLCγ1 and ERK1/2. ITK inhibitor 6 shows antiproliferative activities .
Cat. No.: HY-175407
Target:
Research Areas:
18:0-20:4 PI(3,4,5)P3 (sodium) is an analogue of phosphatidylinositol. Protein-binding to PtdIns-(3,4,5)-P3 is important for cytoskeletal rearrangements and membrane trafficking. PtdIns-(3,4,5)-P3 is resistant to cleavage by PI-specific PLC .
Cat. No.: HY-175984
Target:
Research Areas:
S1P1 agonist 7 is a potent, orally active, and β-arrestin-biased S1P1 agonist (EC50(G‑protein) = 12.7 nM and EC50(β‑arrestin) = 3.23 nM). S1P1 agonist 7 demonstrates potent immunomodulatory activity and a favorable safety profile. S1P1 agonist 7 exhibits excellent metabolic stability, minimal to moderate CYP inhibition, and S1P3-sparing selectivity. S1P1 agonist 7 shows pharmacokinetics, effectively reduces circulating lymphocytes, and significantly alleviates disease severity in experimental autoimmune encephalomyelitis (EAE) mouse models under both prophylactic and therapeutic regimens. S1P1 agonist 7 can be used for multiple sclerosis (MS) research .
Cat. No.: HY-P10833
Cat. No.: HY-185206
CAS No.: 2756388-01-7
BSJ-05-037 is an ITK PROTAC degrader that effectively targets and degrades ITK in T-cell lymphoma cell lines. BSJ-05-037 blocks the activation of the NF-κB/GATA-3 signaling pathway, inhibits PLCγ1 phosphorylation, and reduces the proliferative capacity of T-cell lymphoma cells. BSJ-05-037 enhances the sensitivity of T-cell lymphoma cells to chemotherapy. In mouse models of T-cell lymphoma, BSJ-05-037 induces ITK degradation, reduces GATA-3 expression, decreases tumor volume, and reverses chemotherapy resistance. BSJ-05-037 is applicable to research related to T-cell lymphoma .
Cat. No.: HY-162280
CAS No.: 3034024-77-3
Research Areas:
PROTAC BTK Degrader-9 is a potent BTK PROTAC degrader with a DC50 of 1.29 nM (in Mino cells at 4 h). PROTAC BTK Degrader-9 induces the formation of a stable ternary complex with BTK and the CRBN E3 ubiquitin ligase, thereby mediating proteasomal degradation of BTK in a CRBN-dependent manner. PROTAC BTK Degrader-9 downregulates the RANKL-activated BTK-PLCγ2-Ca 2+-NFATc1 signaling pathway. PROTAC BTK Degrader-9 alleviates alveolar bone resorption in periodontitis models of Mus musculus (house mouse). PROTAC BTK Degrader-9 can be used in research related to periodontitis .
Cat. No.: HY-RS19691
Target:
Research Areas:
Hspg2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Hspg2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-19108
CAS No.: 104795-68-8
Target:
Research Areas:
CI-959 is an orally active cell activation inhibitor. CI-959 selectively suppresses inflammatory cell activation post-receptor signaling via inhibiting calcium influx and weak calmodulin antagonism, without targeting PLC, PKC or NADPH oxidase. CI-959 blocks lung allergic mediator release, anti-IgE bronchial contraction, neutrophil function, T-cell proliferation and DC marker expression while sparing monocytes. CI-959 provides gastric cytoprotection by inhibiting leukocyte adhesion and suppresses tumor motility through F-actin reduction. CI-959 can be used for research on allergies, inflammation, autoimmune diseases, gastric injury, and tumor metastasis .
Cat. No.: HY-RS06449
Target:
Research Areas:
HSPG2 Human Pre-designed siRNA Set A contains three designed siRNAs for HSPG2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-P10658
CAS No.: 143228-35-7
Target:
Research Areas:
Cat. No.: HY-P10119
CAS No.: 205173-94-0
Cat. No.: HY-P10270
CAS No.: 147428-10-2
Cat. No.: HY-125046
CAS No.: 1314212-81-1
Target:
Research Areas:
CYM50374 is a potent antagonist sphingosine-1-phosphate 4 (S1P4) antagonists, with the IC50 of 34 nM .
Cat. No.: HY-170651
CDK4/6/HDAC-IN-1 (Compound N14) is a dual-targeting inhibitor of CDK4/6 and HDAC (IC50: CDK4 = 7.23 nM, CDK6 = 13.20 nM, HDAC1 = 55.66 nM, HDAC6 = 48.38 nM). CDK4/6/HDAC-IN-1 induces cell Apoptosis and G0/G1 phase arrest through HDAC-p21-CDK signaling pathway. CDK4/6/HDAC-IN-1 inhibits hepatocellular carcinoma .
Cat. No.: HY-103411
CAS No.: 74115-10-9
Target:
Research Areas:
SKF83822 hydrobromide is a potent dopamine D1 receptor agonist. SKF83822 hydrobromide activates Gs/olf/adenylyl cyclase (AC)-coupled D1 receptors, but not phospholipase C (PLC)-coupled D1-like receptors .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
